FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

			or Section 30(n) of the investment Company Act of 1940								
1. Name and Address of Reporting Person [*] Subramaniam Somu			2. Issuer Name and Ticker or Trading Symbol <u>Ventyx Biosciences, Inc.</u> [VTYX]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director X 10% Owner							
(Last)			3. Date of Earliest Transaction (Month/Day/Year) 07/28/2023	Officer (give title Other (specify below) below)							
C/O VENTYX BIOSCIENCES, INC. 662 ENCINITAS BLVD, SUITE 250			4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Individual or Joint/Group Filing (Check Applicable Line)							
·				X Form filed by One Reporting Person							
(Street) ENCINITAS	CA	92024		Form filed by More than One Reporting Person							
,			Rule 10b5-1(c) Transaction Indication								
(City)	(State)	(Zip)	Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.								

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Disposed O		red (A) or str. 3, 4 and 5)	5. Amount of Securities Beneficially Owned	6. Ownership Form: Direct (D) or	7. Nature of Indirect Beneficial Ownership
			Code	v	Amount	(A) or (D)	Price	Following Reported Transaction(s) (Instr. 3 and 4)	Indirect (I) (Instr. 4)	(Instr. 4)
Common Stock	07/28/2023		S ⁽¹⁾		611	D	\$37.533(2)	8,556,255	I	See Footnotes ⁽³⁾ (4)(5)
Common Stock	07/31/2023		S ⁽¹⁾		10,803	D	\$37.5854 ⁽⁶⁾	8,545,452	I	See Footnotes ⁽³⁾ (4)(7)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transac Code (Ir 8)		Number		6. Date Exerc Expiration Da (Month/Day/N	Amount of Securities		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				

Explanation of Responses:

1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by NSV Partners III, L.P. on February 24, 2023.

2. Represents the weighted average share price of an aggregate total of 611 shares sold in the price range of \$37.50 to \$37.555. The reporting owner undertakes to provide upon request by the

Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

3. NSV Partners III, L.P. is the general partner of NSV Investments I, L.P., NSV Investments III, L.P., and NSV Investments II, L.P.

4. The reporting person is the majority member and managing member of NSV Partners III GP, LLC, and may be deemed to have voting and dispositive power over the shares owned by each entity of which NSV Partners III, L.P. is general partner. The reporting person is the majority member and managing member NSV Partners II, LLC. The reporting person is the majority member and managing member of New Science Ventures, LLC. The reporting person disclaims beneficial ownership over the shares owned by each of the NSV Funds (as defined below), except to the extent of his pecuniary interest therein.

5. The shares beneficially owned by the reporting person consists of: (i) 5,004,071 shares held by NSV Investments I, L.P., (ii) 978,835 shares held by NSV Investments III, L.P., (iii) 1,498,226 shares held by NSV Partners III, L.P., (iv) 434,423 shares held by New Science Ventures, LLC, (v) 408,520 shares held by NSV Partners II, LLC, and (vi) 232,180 shares held by NSV Investments II, L.P. (collectively, the "NSV Funds"). The NSV Funds disclaim beneficial ownership over the shares owned by them, except to the extent of their pecuniary interest therein.

6. Represents the weighted average share price of an aggregate total of 10,803 shares sold in the price range of \$37.50 to \$37.82. The reporting owner undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

7. The shares beneficially owned by the reporting person consists of: (i) 5,004,071 shares held by NSV Investments I, L.P., (ii) 978,835 shares held by NSV Investments III, L.P., (iii) 1,487,423 shares held by NSV Partners III, L.P., (iv) 434,423 shares held by NSV Investments II, L.P., (iv) 434,423 shares held by NSV Investments II, L.P., (iv) 434,423 shares held by NSV Investments II, L.P., (iv) 434,423 shares held by NSV Investments II, L.P., (iv) 434,423 shares held by NSV Investments II, L.P., (iv) 434,423 shares held by NSV Investments II, L.P., (iv) 434,423 shares held by NSV Investments II, L.P., (iv) 434,423 shares held by NSV Investments II, L.P., (iv) 434,423 shares held by NSV Investments II, L.P., (iv) 434,423 shares held by NSV Investments II, L.P., (iv) 434,423 shares held by NSV Investments II, L.P., (iv) 434,423 shares held by NSV Investments II, L.P. The NSV Funds disclaim beneficial ownership over the shares owned by them, except to the extent of their pecuniary interest therein.

Remarks:

/s/ Christopher Krueger, as

Attorney-in-Fact

08/01/2023

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

 \ast If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

OMB APPROVAL

OMB Number: 3235-0287 Estimated average burden hours per response: 0.5